Elevance Health (ELV) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Elevance Health (ELV) right now is Carelon services and pharmacy expansion: Carelon, which includes CarelonRx and risk-based care services, grew operating revenue about 33 percent in 2025 to roughly $71.7 billion, aided by the CareBridge acquisition. Revenue (TTM) is ~$200 billion. If that keeps playing out, the setup is favourable; the risk to it is the dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. No one can predict where ELV trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Elevance Health (ELV) higher?
1. Carelon services and pharmacy expansion
Carelon, which includes CarelonRx and risk-based care services, grew operating revenue about 33 percent in 2025 to roughly $71.7 billion, aided by the CareBridge acquisition. This shifts Elevance's mix toward higher-growth, capital-lighter services revenue that is less exposed to pure insurance underwriting swings. Management frames Carelon as a core margin and growth engine alongside traditional insurance.
2. Government programs repricing
Medicare Advantage membership growth and Medicaid rate updates are central to the 2026 story. Elevance has been pressing state partners for Medicaid rates that better reflect the acuity of members retained after post-pandemic redeterminations. If premium yields catch up to medical cost trend, margins in government business can normalize over the coming year.
3. Capital return and low valuation
Elevance generates substantial cash, funding dividends and buybacks, and trades at a trailing P/E around 11 to 12 times, well below the broad market. The company reaffirmed its 2026 earnings and cost targets, and continued EPS growth combined with share repurchases is a key part of how the stock is positioned relative to its modest multiple.
4. Diversification across the insurance book
A spread across commercial (employer and individual), Medicare, Medicaid, and ACA marketplace plans gives Elevance multiple demand pools. Softness in one line, such as Medicaid cost pressure, can be partly offset by strength elsewhere, including a noted shift toward bronze-tier ACA plans. This breadth is the buffer against any single program's cost shock.
What could weigh on ELV?
The dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. Elevance is heavily exposed to government programs, so Medicaid rate adequacy, Medicare Advantage rate notices, and ACA subsidy policy are all regulatory swing factors outside its control. Integration risk from acquisitions like CareBridge, litigation and audit exposure common to large payers, and the political sensitivity of health insurer profits add further uncertainty. Because insurance margins are thin, a few points of adverse medical loss ratio can move earnings sharply, which is a key reason the stock carries a low multiple.
Where ELV trades today
A forecast starts from where the stock actually is. These are ELV's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for ELV as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a ELV forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ELV guide and whether ELV is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ELV outlook
The bottom line: what is driving Elevance Health (ELV) is Carelon services and pharmacy expansion, with revenue (ttm) at ~$200 billion. If that keeps playing out the setup is favourable; the risk is the dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. No one can predict the price, so treat any ELV forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ELV with Walnut
Use Elevance Health as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Elevance Health (ELV)?
+
No one can reliably predict where ELV will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Elevance Health higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ELV higher?
+
The main growth drivers are Carelon services and pharmacy expansion; Government programs repricing; Capital return and low valuation. Whether they play out is the real question, not a guaranteed path.
What are the risks to ELV?
+
The dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. Elevance is heavily exposed to government programs, so Medicaid rate adequacy, Medicare Advantage rate notices, and ACA subsidy policy are all regulatory swing factors outside its control. Integration risk from acquisitions like CareBridge, litigation and audit exposure common to large payers, and the political sensitivity of health insurer profits add further uncertainty. Because insurance margins are thin, a few points of adverse medical loss ratio can move earnings sharply, which is a key reason the stock carries a low multiple.
Will ELV stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Elevance Health's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ELV a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ELV "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.